121772-84-7

Basic information

• Product Name: methyl 2-iodo-3-bromobenzoic acid
• Synonyms: methyl 2-iodo-3-bromobenzoic acid
• CAS NO: 121772-84-7
• Molecular Weight: 340.943
• Mol File: 121772-84-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 103-112 °C(Press: 0.02 Torr)
• Density: 2.059±0.06 g/cm3(Predicted)
• CAS DataBase Reference: methyl 2-iodo-3-bromobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-iodo-3-bromobenzoic acid(121772-84-7)
• EPA Substance Registry System: methyl 2-iodo-3-bromobenzoic acid(121772-84-7)

Safety Data

• Hazardous Substances Data: 121772-84-7(Hazardous Substances Data)

Usage

General Description

Methyl 2-iodo-3-bromobenzoic acid is a chemical compound with the molecular formula C8H6BrIO2. methyl 2-iodo-3-bromobenzoic acid is a derivative of benzoic acid and contains both iodine and bromine atoms attached to the benzene ring. It is also esterified with a methyl group, which makes it more soluble in organic solvents. Methyl 2-iodo-3-bromobenzoic acid is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its structure and reactivity make it a valuable building block for creating more complex molecules with specific properties.

Upstream product

• 20776-51-6 2-amino-3-bromo benzoic acid 
• 74-88-4 methyl iodide 
• 615-36-1 2-bromoaniline 
• 20780-74-9 7-bromoisatin 
• 104670-74-8 methyl 2-amino-3-bromobenzoate 

Downstream Products

• 1261653-43-3 methyl 3-bromo-2-cyanobenzoate 
• 4269-17-4 4-bromo-9H-fluorene-9-one 
• 1161009-89-7 2-(9,9'-spirobi[fluoren]-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1161009-88-6 4-bromo-9,9’-spirobi[9H-fluorene] 

Relevant articles and documents

Biphenyl compound as well as preparation method and medical application thereof

The invention discloses a biphenyl compound as well as a preparation method and medical application thereof, the structure of the biphenyl compound is shown as a formula (I) or a formula (II), and thebiphenyl compound or pharmaceutically acceptable salt, tautomer, meso-isomer, raceme, stereoisomer, metabolite, metabolite precursor, prodrug or solvate thereof is a PD-L1 inhibitor. The compound hasa remarkable inhibiting effect on the interaction of PD-1 and PD-L1 protein, so that the compound can be applied to the preparation of PD-L1 inhibitors and immunomodulator drugs for preventing or treating tumors, autoimmune diseases, organ transplant rejection, infectious diseases and inflammatory diseases.

EBNA1 INHIBITORS AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.